Extended Data Figure 10: Expression of CD36 correlates with poor prognosis in several human tumours, and inhibition of CD36 inhibits metastasis of human melanoma and luminal A breast carcinoma cell lines.

a, Correlation of CD36-associated signature expression or CD36 expression with overall and disease-free survival for patients. Red and green lines denote patients whose tumours expressed signatures or CD36 higher and lower than the median, respectively. b, BLI signals from metastasis developed in NSG mice injected with MCF-7 (PLKO, n = 10; Cd36 shRNA, n = 10 mice) and 501mel (PLKO, n = 10; Cd36 shRNA, n = 10 mice) cells (for breast MCF-7, *P = 0.04, two-tailed t-test and for melanoma 501mel, ***P = 0.0001 in liver metastasis and **P = 0.0003 in lung metastasis, two-tailed t-test). c, Relative proportion of developed metastases from mice in a (*P = 0.05, two-tailed Fisher’s exact test). d, BLI signals from primary tumours and relative blood and lung GFP RNA levels measured by qPCR analysis after intravenous injection of Detroit-562 and SCC-25 cells transduced with empty vector (control) or shRNA Cd36. Samples were collected immediately after injection (T-0h) and 12 and 48 h (T-12h and T-48h, respectively) after injection (n = 3 animals per time point in each of the groups; *P ≤ 0.05, two-tailed t-test). Data in b, d, are given as the mean ± s.e.m. e, GSEA of EMT genes in CD36⁺ and CD36⁻ cells sorted from primary oral lesions (generated from CD44^bright inoculated cells), or from lymph node metastases (generated from CD36⁺ CD44^bright inoculated cells). CD36⁻ cells express higher levels of EMT genes than CD36⁺ cells in both the primary lesion and lymph node metastases. Genes are ranked by t-statistic value. Enriched populations are indicated for each of the plots. Lower panels show the GSEA analysis of the same cohort of EMT genes compared between lymph node metastases and primary oral lesions within CD36⁺ cells or CD36⁻ cells. Source data from mouse experiments are in Supplementary Information.

Source data